Preoperative human recombinant erythropoietin reduces allogenic blood transfusion .
Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty.
Int Orthop. 2012 Apr;36(4):703-9. Epub 2011 Oct 1.93 patients undergoing total hip arthroplasty were randomized to differing preoperative dosing regimes of human recombinant erythropoietin (rHu-EPO) to elucidate its affect on preoperative blood donation and intra-operative blood transfusions. Patients received either a once weekly i.v of 30000 IU rHu-EPO, a twice weekly i.v. of 15000 IU rHu-EPO, or no rHu-EPO. All groups received an oral does of ferrous II sulphate. Results indicate that patients receiving rHu-EPO were able to successfully donate 2 units of blood preoperatively and required fewer intra-operative allogenic blood transfusions compared to controls.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
